Cargando…
Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma
INTRODUCTION: Glaucoma is a known complication of uveitis, and may require glaucoma tube shunt implantation for intraocular pressure (IOP) control. The success of glaucoma tube shunt implantation in the setting of a local ocular steroid depot in uveitic glaucoma remains unknown. The purpose of this...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125127/ https://www.ncbi.nlm.nih.gov/pubmed/27638839 http://dx.doi.org/10.1007/s40123-016-0066-2 |
_version_ | 1782469936095952896 |
---|---|
author | Zivney, Mark Lin, Phoebe Edmunds, Beth Parikh, Mansi Takusagawa, Hana Tehrani, Shandiz |
author_facet | Zivney, Mark Lin, Phoebe Edmunds, Beth Parikh, Mansi Takusagawa, Hana Tehrani, Shandiz |
author_sort | Zivney, Mark |
collection | PubMed |
description | INTRODUCTION: Glaucoma is a known complication of uveitis, and may require glaucoma tube shunt implantation for intraocular pressure (IOP) control. The success of glaucoma tube shunt implantation in the setting of a local ocular steroid depot in uveitic glaucoma remains unknown. The purpose of this study was to determine whether patients who underwent combined glaucoma tube shunt (Ahmed) and fluocinolone acetonide (Retisert™, Bausch + Lomb, Bridgewater, NJ, USA) implantation have superior outcomes compared to patients with Ahmed implants only in the setting of uveitic glaucoma. METHODS: All participants were studied retrospectively and underwent Ahmed implantation alone or with existing/concurrent Retisert implantation (combined group) at a single academic institution. The main outcome measures were IOP, visual acuity (VA), number of IOP-lowering medications, and adverse events at 6 months after Ahmed implantation. Secondary outcome measures included adverse events and surgical success at 6 months after Ahmed implantation. RESULTS: Mean IOP at 6 months after Ahmed implantation was 15.3 ± 4.8 and 15.1 ± 4.9 mm Hg in the Ahmed only group (n = 17) and the combined group (n = 17), respectively (p = 0.89). The mean number of IOP-lowering medications at 6 months after Ahmed implantation was 1.7 ± 1.0 and 1.8 ± 1.0 in the Ahmed only group and the combined group, respectively (p = 0.86). Mean VA at 6 months after Ahmed implantation was 0.35 ± 0.29 and 0.42 ± 0.33 log mean angle of resolution in the Ahmed only group and the combined group, respectively (p = 0.50). No significant differences in surgical success or adverse events were noted between the two groups. CONCLUSION: At 6 months, no significant differences in mean IOP, mean number of IOP-lowering medications, VA, surgical success, or adverse events were noted between Ahmed implantation alone or combined Ahmed and Retisert implantation in patients with uveitic glaucoma. |
format | Online Article Text |
id | pubmed-5125127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-51251272016-12-13 Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma Zivney, Mark Lin, Phoebe Edmunds, Beth Parikh, Mansi Takusagawa, Hana Tehrani, Shandiz Ophthalmol Ther Original Research INTRODUCTION: Glaucoma is a known complication of uveitis, and may require glaucoma tube shunt implantation for intraocular pressure (IOP) control. The success of glaucoma tube shunt implantation in the setting of a local ocular steroid depot in uveitic glaucoma remains unknown. The purpose of this study was to determine whether patients who underwent combined glaucoma tube shunt (Ahmed) and fluocinolone acetonide (Retisert™, Bausch + Lomb, Bridgewater, NJ, USA) implantation have superior outcomes compared to patients with Ahmed implants only in the setting of uveitic glaucoma. METHODS: All participants were studied retrospectively and underwent Ahmed implantation alone or with existing/concurrent Retisert implantation (combined group) at a single academic institution. The main outcome measures were IOP, visual acuity (VA), number of IOP-lowering medications, and adverse events at 6 months after Ahmed implantation. Secondary outcome measures included adverse events and surgical success at 6 months after Ahmed implantation. RESULTS: Mean IOP at 6 months after Ahmed implantation was 15.3 ± 4.8 and 15.1 ± 4.9 mm Hg in the Ahmed only group (n = 17) and the combined group (n = 17), respectively (p = 0.89). The mean number of IOP-lowering medications at 6 months after Ahmed implantation was 1.7 ± 1.0 and 1.8 ± 1.0 in the Ahmed only group and the combined group, respectively (p = 0.86). Mean VA at 6 months after Ahmed implantation was 0.35 ± 0.29 and 0.42 ± 0.33 log mean angle of resolution in the Ahmed only group and the combined group, respectively (p = 0.50). No significant differences in surgical success or adverse events were noted between the two groups. CONCLUSION: At 6 months, no significant differences in mean IOP, mean number of IOP-lowering medications, VA, surgical success, or adverse events were noted between Ahmed implantation alone or combined Ahmed and Retisert implantation in patients with uveitic glaucoma. Springer Healthcare 2016-09-16 2016-12 /pmc/articles/PMC5125127/ /pubmed/27638839 http://dx.doi.org/10.1007/s40123-016-0066-2 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Zivney, Mark Lin, Phoebe Edmunds, Beth Parikh, Mansi Takusagawa, Hana Tehrani, Shandiz Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma |
title | Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma |
title_full | Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma |
title_fullStr | Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma |
title_full_unstemmed | Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma |
title_short | Combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) Implantation Compared to Ahmed Alone in Uveitic Glaucoma |
title_sort | combined glaucoma tube shunt (ahmed) and fluocinolone acetonide (retisert™) implantation compared to ahmed alone in uveitic glaucoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125127/ https://www.ncbi.nlm.nih.gov/pubmed/27638839 http://dx.doi.org/10.1007/s40123-016-0066-2 |
work_keys_str_mv | AT zivneymark combinedglaucomatubeshuntahmedandfluocinoloneacetonideretisertimplantationcomparedtoahmedaloneinuveiticglaucoma AT linphoebe combinedglaucomatubeshuntahmedandfluocinoloneacetonideretisertimplantationcomparedtoahmedaloneinuveiticglaucoma AT edmundsbeth combinedglaucomatubeshuntahmedandfluocinoloneacetonideretisertimplantationcomparedtoahmedaloneinuveiticglaucoma AT parikhmansi combinedglaucomatubeshuntahmedandfluocinoloneacetonideretisertimplantationcomparedtoahmedaloneinuveiticglaucoma AT takusagawahana combinedglaucomatubeshuntahmedandfluocinoloneacetonideretisertimplantationcomparedtoahmedaloneinuveiticglaucoma AT tehranishandiz combinedglaucomatubeshuntahmedandfluocinoloneacetonideretisertimplantationcomparedtoahmedaloneinuveiticglaucoma |